Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: DrugBank:EXPT01586 (
G418
)
2,237
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It has been proven that maternally expressed 3 (
MEG3
), a long non-coding RNA (LncRNA), is down-regulated and inversely correlated with prognosis in various types of cancer, including bladder cancer (BC). Nevertheless, the role of
MEG3
in BC has not been fully identified. Herein, we found that
MEG3
expression was reduced in 21 BC tumor tissue samples compared to corresponding adjacent tissues. We then established T24 and 5637 cells with a stably integrated expression of
MEG3
by
G418
resistance screening, and data revealed that the BC cells over-expressing
MEG3
displayed weaker migration and invasion ability than control cells. The expression and activity of matrix metalloproteinase (MMP)2 and MMP9 were down-regulated when
MEG3
was over-expressed. Moreover,
MEG3
over-expression sensitized BC cells to the chemotherapy drug cisplatin (DDP). DDP treatment significantly induced cell apoptosis, down-regulated bcl2 expression, and up-regulated cleaved-caspase-3 and bax expression in BC cells with
MEG3
over-expression.
MEG3
and p53 can also stimulate mutual expression in BC cells, thus indicating a potential positive feedback loop of
MEG3
and p53. Our combined results suggest that over-expression of
MEG3
inhibits migration and invasion and enhances DDP chemo-sensitivity in bladder cancer cells.
...
PMID:Up-regulation of LncRNA MEG3 inhibits cell migration and invasion and enhances cisplatin chemosensitivity in bladder cancer cells. 2994 Jul 69
